Live feed07:27:00·108dPRReleasevia QuantisnowCardiol Therapeutics Achieves Key 50% Patient Enrollment Milestone in Pivotal Phase III MAVERIC Trial in Recurrent PericarditisByQuantisnow·Wall Street's wire, on your screen.CRDL· Cardiol Therapeutics Inc.Health Care
